Abstract Alterations of DNA copy number are believed to be important indicators of tumor progression in human astrocytoma. We used an array of bacterial artificial chromosomes to map relative DNA copy number in 50 primary glioblastoma multiforme tumors at f1.4-Mb resolution.We identified 33 candidate sites for amplification and homozygous deletion in these tumors.We identified three major genetic subgroups within these glioblastoma multiforme tumors: tumors with chromosome 7 gain and chromosome10 loss, tumors with only chromosome 10 loss in the absence of chromosome 7 gain, and tumors without copy number change in chromosomes 7 or 10. The significance of these genetic groups to therapeutics needs further study.
Studies suggest that astrocytic brain tumor behavior is related to genetic defects acquired over the course of tumor development (1 -6) . It is believed that understanding these genetic defects will help predict response to treatment and patient outcome. Previous studies using comparative genomic hybridization (CGH; refs. 7, 8) related radiation sensitivity of tumors and patients' survival to copy number aberrations (CNA) on several chromosomes (2, 3) . This report describes CNAs identified on a bacterial artificial chromosome (BAC) array of f1.4-Mb resolution [array comparative genomic hybridization (aCGH)], in a set of 50 glioblastoma multiforme (GBM).
We compared specificity and sensitivity of the chromosome CGH and aCGH techniques by comparing array and chromosome CGH in the same tumor samples, by counting fluorescence in situ hybridization (FISH) signals generated by BAC clones used in the array, and by using real-time quantitative PCR. The results obtained by aCGH confirmed other characterizations of the GBM genome.
Analysis of high-resolution aCGH data identified genetic subgroups in this set of GBM and loci for candidate oncogenes and tumor suppressor genes, many of which were previously unknown. We expect that future higher resolution studies of these regions will lead to identification of target genes for therapy.
Materials and Methods
Cell lines. The cell lines used in this study (SF767, SF126, U343MG, and SF210) were obtained from the Tissue Bank at the Brain Tumor Research Center, University of California, San Francisco (UCSF; ref. 9 ). Cells were cultured in minimal essential medium with Earle's buffered salt solution supplemented with 10% FCS and nonessential amino acids.
Tumor DNA. Fifty tumor samples (GBM, grade 4 astrocytoma) were obtained from the tissue bank at the Brain Tumor Research Center, UCSF. All patients signed consent for specimens to be used for research purposes. The samples were originally chosen for evaluation using chromosome CGH (8) . Tumor specimens were snap-frozen in liquid nitrogen immediately after resection and stored at À80jC. Tumors were diagnosed by the Division of Neuropathology at UCSF according to WHO classification (10) . Sections on both sides contiguous to the processed specimens were histologically assessed to determine the percentage of tumor cells present in the tissue before DNA extraction. Specimens with 50% or more tumor cells in the adjacent sections were selected for DNA extraction.
Bacterial artificial chromosome array. We used an array with 2,246 BAC clones developed at UCSF for aCGH (11, 12) . BAC clones were spotted in triplicate on chromium-coated glass slides. Approximately 10% of the genome was represented on the array. The average resolution was f1. 4 Mb, but the coverage varied from chromosome to chromosome. The Y chromosome was not represented on this version of the array. BAC clones that FISH mapped to more than one locus were excluded from our analysis.
Array comparative genomic hybridization. We used random priming (13) to label 300 to 500 ng tumor DNA with Cy3-labeled deoxynucleotide triphosphate and sex-matched normal DNA with Cy5-labeled deoxynucleotide triphosphate. The labeled probes were mixed with 50 Ag human Cot-1 DNA, precipitated with sodium acetate and ethanol, and resuspended in 2.5 AL of water, 2.5 AL of yeast tRNA (100 Ag/mL), 10 AL of 20% SDS, and 35 AL of hybridization mix [15% dextran sulfate in 2Â SSC and 50% formamide (pH 7.0)]. The resulting solution was denatured at 80jC for 10 minutes, incubated at 37jC for 1 hour, and applied to an array preblocked for 30 minutes with 50 Ag of herring sperm DNA in 5 AL water, 10 AL 20% SDS, and 35 AL hybridization mix. Hybridizations were done at 37jC for 48 hours in a sealed chamber on a slowly rocking stage. Arrays were washed for 15 minutes at 45jC in 50% formamide/2Â SSC (pH 7.0), and for 10 minutes at room temperature in 0.1 mol/L Na 2 HPO 4 with 0.1% NP40 (pH 8.0). Arrays were mounted in 0.1 Amol/L 4V,6-diamidione-2-phenylindole in 90% glycerol to visualize spotted BACs, and fluorescent images were acquired using a 16-bit charge-coupled device camera with appropriate filter sets (11) .
Image analysis and data acquisition. The ''spot'' image analysis program (14) was used to assign pixels to the foreground and background for each DNA spot. We evaluated data quality and calculated a relative ratio (RR) of tumor copy number to normal DNA copy number at loci represented on the array. The RR was defined as the ratio of background-subtracted signal intensities for tumor (Cy3) and normal (Cy5) DNA, normalized to the median RR of that hybridization. We required data from at least two of three replicates for each BAC, with a SD z0.1. RR values were converted to log 2 RR values and plotted against the map position of the BACs on each chromosome.
Copy number aberration frequency map and cutoffs. We constructed a histogram from normalized log 2 RR values from each hybridization ( Fig. 1A and B) , and fit a mixture of three Gaussian distributions to the data according to an algorithm described in Hodgson et al. (15) . We defined gains and losses as values greater than or less than 3 SD from the mode of the central Gaussian. The average SD of the central Gaussians for our set of samples was 0.1 F 0.025. Hybridizations with a SD of >0.15 for the central Gaussian were defined as poor quality and rehybridized. Each locus in each tumor was scored as gain, loss, or no change, and this converted data set was used to calculate and plot the frequency of gain and loss at each locus (BAC) on the array.
Comparing chromosome comparative genomic hybridization and array comparative genomic hybridization. Chromosome CGH was done as described by Mohapatra et al. (16) . We compared aCGH data from the same set of 50 GBM with chromosome CGH data (16) . Two investigators independently scored standard CGH profile CNAs as sure loss (À2), possible loss (À1), normal (0), possible gain (1), sure gain (2), or amplification (3). Scoring differences were resolved by mutual agreement. We used 3 SD aCGH cutoff values to score gains, losses, and amplifications and compared them with the chromosomal CGH profile scores. CNAs determined by aCGH were defined as ''sure'' (À2 or 2) if >50% of BACs in the region were aberrant, ''possible'' (À1 or 1) if <50% of BACs in the region were aberrant, and ''amplified'' if log 2 RR values of each BAC in that region were z2. We scored a region as normal if there were occasional single-aberrant BACs with an otherwise normal profile.
Quantitative microsatellite analysis. Quantitative microsatellite analysis (17) was done at three loci on 7q in a set of 14 GBM selected from our DNA inventory. BAC sequences were mined for possible CA repeat elements and flanking primers were designed with ''name'' software (Applied Biosystems, Foster City, CA). The forward and reverse primer sequences were as follows: locus 1, 5V -ATTATTGGC-CAGTTGGTTCT-3V , 5V -ACAAGGAATAATATCCAGAAGA-3V ; locus 2, 5V -TGAAGCACCTGTCCAACC-3V , 5V -ACAAGGAATAATATCCAGAAGA-3V ; and locus 3, 5V -CTTCAAACTTTAACTTCC, 5V -TTTACATAGCAAC-CATTGCA-3V . A pool of six primer sets from microsatellite loci served as the control for a diploid locus as previously described (17) . Reactions were done in triplicate with 5 ng of genomic DNA using the ABI 7700 (Applied Biosystems). The average Ct value for each set of triplicates was used to calculate copy number. Gains and losses at loci were determined based on a tolerance interval previously calculated from the results of 167 amplification reactions done on DNA obtained from 10 individuals (17) . Based on this tolerance interval, values <1.58 were defined as losses, whereas values >2.53 were defined as gains. In this study, because one locus gave a value of 2.7 in a sample of control DNA, we scored more conservatively, defining values >2.7 as gain.
Fluorescence in situ hybridization. BAC DNA was extracted using a Qiagen tip-500 column (Valencia, CA) and labeled with digoxigenin-11-dUTP or biotin-14-dUTP (Roche Molecular Biochemicals, Indianapolis, IN) by nick translation. Touch preparations were made from frozen tumor tissue, and metaphase spreads were prepared from cell lines SF767, SF126, U343, and SF210 and from normal leukocytes (16) . All hybridizations were done as described previously (16) . BAC clones used for interphase FISH were physically mapped using the normal metaphase spreads, and the absolute copy number of loci was determined by evaluating at least 200 interphase cells.
Unsupervised clustering. We converted the RR value for each BAC clone in each tumor to a score of 1 (gain/amplified), 0 (no change), or À1 (loss) based on the 3 SD standard described above and analyzed the converted data set with Cluster 3.0 (18), choosing mean centered (no filtering) and centroid linkage (correlation uncentered) calculations. We viewed the results in Treeview (18) . Gain, loss, and no change were represented in the final heat map as red, green, and black, respectively. Quantitative PCR. We assayed copy number using quantitative microsatellite analysis at 3 loci on 7q to validate aCGH data in 14 tumors. Table 1 Table 1 ). Thus, 37 of 42 comparisons between aCGH and QPCR agreed.
Chromosome comparative genomic hybridization and array comparative genomic hybridization comparisons. Table 2 compares CNAs scored by chromosome CGH and aCGH. Of 1,059 comparisons, 998 agreed and 64 (f6%) were discordant. Fortyseven ''possible'' chromosome CGH gains were scored as ''no change'' by aCGH, 8 possible chromosome CGH losses were scored as ''no change'' by aCGH, and 2 ''sure'' chromosome CGH losses were scored as ''possible'' by aCGH.
FISH validation of array comparative genomic hybridization for copy number aberrations of single bacterial artificial chromosome length. We were concerned about the quality of data from individual BAC clones with RRs that did not match their BAC neighbors. Mismapping or other technical or handling errors could lead to apparent single-clone aberrations. We selected nine BAC clones displaying such single-clone aberrations in one or more cell lines and compared copy number by aCGH (V exp ) and FISH (V obs ) in four cell lines ( underestimates DNA copy number when the copy number is high. The Shapiro-Wilk normality test revealed that the ratios of V exp /V obs were normally distributed at a 0.05 confidence level, with an estimated mean value of 0.94 (SD, 0.15).
Copy number aberration frequency map. Figure 5 maps the frequency of CNAs at BAC loci in 50 GBM. The map does not distinguish between gain and amplification or between homozygous and heterozygous loss. The maps suggest that whole chromosome loss and gain take place primarily on chromosomes 10 (loss), 13 (loss), and 7 (gain). Approximately 75% of our samples lost the region around INK4a/ARF (9p21) and 94% had gained or amplified EGFR. Approximately 40% had gain of whole chromosome 7 and f60% had loss of whole chromosome 10. 6q was lost in f15% and chromosome 19 was gained in f15%. Small regions (one or more than one consecutive BAC clones) of gain and/or loss occurred on all other chromosomes. Table 4 lists 55 BACs at 33 loci (more than one consecutive BAC can map to a single locus) wherein log 2 RRs were z2 or VÀ1. In a diploid tumor, this theoretically represents a locus with >8 copies (RR z2) or <1 copy (RR VÀ1). These loci included oncogenes (e.g., EGFR, cMYC, PDGFRA, MDM2, CDK4) and tumor suppressors (e.g., INK4a/ARF, PTEN) previously reported in GBM, as well as loci not reported in earlier studies. Among the 55 BAC clones, 18 were single BAC clone losses and 2 were single BAC clone amplifications. Two consecutive BAC clones were lost at one 10q locus in one tumor; 6 consecutive BAC clones were lost at one locus on 9p in another tumor. There were six amplified regions encompassing 2 to 6 consecutive BAC clones at 1q, 3q, 4q, 7p, 7q, and 12q. Figure 6A highlights the EGFR amplicon in this set of tumors. We observed EGFR amplification in 11 of 47 cases ( Table 4 ). The amplicon length varied from a single BAC (lower limit Figure 6B displays the region of INK4a/ARF deletion in this set of tumors. Homozygous deletion at INK4a/ARF usually encompasses a single BAC clone, but it can extend up to f400 kb toward 9pter and f200 kb toward the centromere. We observed homozygous deletion of the BAC containing INK4a/ARF in 12 cases; 1 case had homozygous deletions of three consecutive BAC clones and 1 case had homozygous deletions of six consecutive BAC clones. Overall, the INK4a/ ARF region was deleted in 76% of cases, and 28% were homozygous.
We detected presumed heterozygous loss of PTEN in 34 cases and homozygous loss in 1. Our data suggest that additional isolated homozygous losses occur at 1p36. (Table 4) .
Genetic subgroups in grade 4 astrocytoma. Two major genetic subgroups (A and B + C) of grade 4 astrocytoma emerged from unsupervised clustering of aCGH data (Fig. 7) . SAM analysis indicated that relative copy number at 227 BAC clones (false discovery rate <0.7%) differ in these groups: 136 clones mapped to chromosome 7, and 84 clones mapped to chromosome 10, indicating that gain of chromosome 7 and/ or loss of chromosome 10 tends to occur in group B + C. The clones that differ between the genetic subgroups represent f70% of the those we assayed on chromosome 7 and f60% of those we assayed on chromosome 10. Group A (n = 23) 
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Research. has relatively fewer CNAs (236 + 150, ranging from 45 to 488). Group B + C is subdivided into B and C branches, and SAM analysis identified 130 clones (at a false discovery rate of 0.8%) that segregated group B from C; 112 mapped to chromosome 7, and 7 mapped to chromosome 13. Group B (n = 9) lost genetic material on chromosome 10 in all cases, and group C (n = 18) had chromosome 7 gain in all cases and chromosome 10 loss in all but two cases. Other frequently observed aberrations in grade 4 astrocytoma (e.g., loss of 9p, 13q, and 14q) were present in all three groups, but relatively more frequently in groups B and C. Gain of chromosome 19 and gain of chromosome 20 was found primarily in group C, and loss of 6q was primarily found in group B + C.
Clinical data on genetic subgroups. Age and sex data were available for 50 cases, and survival data were available from 47. Figure 8 shows the Kaplan-Meier curve for survival in 47 cases divided into the three genetic groups mentioned above. There was no difference in survival among genetic groups. Average age of patients did not differ by group, although group C tended toward higher mean and median age. In a larger data set (n = 99) of GBMs, including these 50 
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on April 13, 2017. © 2005 American Association for Cancer clincancerres.aacrjournals.org Downloaded from of 10 tend to be older. 5 Age was a highly significant determinant for survival (P = 0.0015), whereas gender was not (P = 0.64).
Discussion
This study suggests that GBM can be categorized into genetic subgroups and validates aCGH for detecting CNAs in GBM. Our data also identified candidate loci for homozygous deletions and amplifications. We compared aCGH results with data obtained by chromosomal CGH, FISH, and quantitative PCR, and conclude that RR obtained from aCGH is a reliable estimate of relative copy number. Moreover, unlike chromosome CGH, aCGH detects homozygous loss and amplicon size and maps CNAs to precise locations in the genome.
Genetic subgroups. Our data suggest that there are genetically distinct subgroups within GBM (Fig. 7) . We identified three provisional genetic subgroups: one with loss of chromosome 10 and gain of chromosome 7 (group C), a second with loss of chromosome 10 only (group B); and a third without chromosome 10 loss or chromosome 7 gain (group A). If the mechanisms that underlie malignant behavior in these genetic subgroups substantially differ, we expect that subgroups may behave differently and be responsive to different therapies. We have observed that subgroup C is associated with typical GBM survivors and that group A contains both typical and long-term survivors 6 (20) . This suggests that tumor behavior and GBM genetic subgroups are related.
Average survival did not vary among genetic groups in the present study (Fig. 8) . This result may reflect a study population with few long-term survivors. Three patients in the present study were long-term survivors and lived between 2 and 3 years after diagnosis. A study of 34 cases by Nigro et al. 6 included 10 long-term survivors who lived 131 to 459 weeks (average, 231 weeks) after diagnosis and revealed a relationship between survival and genetic subgroup. Thus, differences in study sample selection are likely an important factor in differences in results from these two studies.
One current hypothesis divides GBM into ''primary'' and ''secondary'' types depending on the length of symptoms. Primary GBM progresses quickly and secondary GBM has longer progression times (21) . The relationship of primary and secondary tumors to the genetic subgroups we describe is unknown. p53 mutation, 10q (without 10p) loss, and loss of heterozygosity of 19q have been associated with secondary GBM, whereas EGFR amplification, p16 homozygous deletion, and PTEN mutation have been associated with primary GBM (22 -25) . Our current data suggest that EGFR amplification occurs primarily in group C (we identified 2 in group A, 1 in B, and 8 in C) and that p16 homozygous deletion occurs in all subgroups (6 in group A, 3 in B, and 5 in C). The one case with PTEN homozygous deletion was in group C. Of nine cases that had loss of 10q without loss of 10p, 8 were in group A and 1 was in group C. Of 13 cases with substantial 19q loss, 8 belonged to group A, 2 belonged to group B, and 2 belonged to group C. This suggests that the genetic subgroup C may have a relationship to primary designation with respect to EGFR amplification and genetic subgroup A may have a relationship to secondary designation with respect to 10q loss (without 10 p loss) and 19q loss.
Age was a strong predictor of survival (P = 0.0015), as previously reported (4, 26, 27) . However, we did not find any relationship between age and genetic subgroups.
Amplifications. aCGH maps amplification events very clearly. Previous reports identified EGFR amplification in 35% to 40% of grade 4 astrocytomas (26 -29) . The differences in amplification frequency could result from different assay sensitivities or from different definitions of amplification. For example, studies using Southern blotting (28) and reverse transcription -PCR in tumor biopsy samples (26) detect a >5-fold increase in EGFR copy number in 49% of cases and a 1.2-fold increase in f77%. We found increased EGFR copy number in 94% of our cases. FISH-based studies report highlevel double-minute EGFR amplifications in over 10% of cells in 33% of cases (27) 
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Research. (30) reports EGFR amplification in isolated cells at the invasive edge of tumor. aCGH might detect this as simple copy number gain. Because we saw whole chromosome 7 gain in f40% of cases but EGFR copy number gain in f94% (say 95% and above), an extensive FISH study might identify more cases of single isolated cells with EGFR amplification. Tandem duplications of EGFR might also account for our results. These have been reported for EGFR (31) , for other regions on 7q (32) , and for loci on other chromosomes 7 in glioma cell lines. FISH may not be able to detect this type of genetic aberration because the extra copy could be juxtaposed to its parent, and Southern blotting may not be sensitive enough to detect the copy number difference. The biological effects of such low-level copy number increases have yet to be investigated.
Our data suggest that EGFR amplicon size varies among our tumor set (Fig. 6A) , from <1 to f5 Mb. Because hundreds of copies of the EGFR amplicon can be present in a single GBM tumor cell (29, 33) , other genes located in the amplicon could affect tumor behavior; for example, 7p11.2 contains at least eight known genes. Our data from 12q suggests a similar situation-coamplification of CDK4, GLI1, and MDM2 can depend on amplicon size. This situation also needs to be investigated at loci on 1q32.1 (GAC1; ref. 34 38, 39) . The UCSC database (July 2003 freeze) suggests the amplicon at 1q32 contains 3 other known genes, at 3q26 contains 19 known and 3 nonannotated genes, at 4q12 contains 4 known and 4 nonannotated genes, at 7q31.s contains 7 known genes, and at 12q13.3-15 contains 33 known and 6 nonannotated genes. The biological and clinical significance of amplicon size and structure has not been thoroughly investigated.
Our data identify gains and amplifications at several loci linked to oncogenes in other tumors, but not frequently associated with GBM. For example, gain of loci at 1q31.1-31.2 and 7q21 occurs in many tumors, and amplifications at these sites occur in a few (Table 4 ; Fig. 5 ). At least two protooncogenes, jun (40, 41) and CYP2J (42) , are located at 1q31.1-31.2 and CDK6 is located at 7q21 (43) .
Deletions. aCGH distinguishes homozygous deletions from single-copy losses (Fig. 3) . Our aCGH results suggest that 28% of our GBM had homozygous INK4a/ARF deletions (Fig. 6B) , and 48% had single-copy deletions. Other studies have reported homozygous INK4a/ARF deletions in 33% to 55% of GBM (44 -46) and f70% of GBM xenografts (47) , hemizygous deletion in f12% (45, 48) , and possible epigenetic inactivation in 3% to 24% (45, 49) . Our measurements evaluate genomic 100-to 150-kb BAC inserts, so that homozygous deletions much smaller than the BAC size might be missed. This may in part account for our relatively low frequency of homozygous deletions. The INK4Aa gene is a tumor suppressor on 9p targeted for homozygous loss in GBM. We find that the size of the homozygous deletion varies. It is possible that other genes located in this region affect tumor behavior, consistent with the hypothesis that more than one tumor suppressor gene is located on 9p (50 -53) .
aCGH indicated that 34 cases lost a single copy of the tumor suppressor gene PTEN, 1 case lost both copies, and 12 cases had no relative loss (data not available in 3 cases). The results agree with previous reports of 70% to 80% loss of the PTEN region (8) . Because mutation of PTEN occurs in <10% to 30% of primary GBM (54, 55) , other mechanisms of PTEN inactivation or AKT activation may exist. For example, there are likely cases of phosphatidylinositol 3-kinase amplification in our tumor set. We have not found literature that reports the frequency of activated AKT in GBM.
There have been reports suggesting that cancers inactivate tumor suppressor genes at 11p13-14.1 (56) and 14q23.3-24.1 (57) . We mapped both heterozygous and homozygous losses in these regions (Table 4 ; Fig. 5 ). However, many candidate loci we mapped (e.g., 4q33, 5p14.3-15.1, 5q33.2, 6p22.3, 8p21, 8qter, 10q22.2, 10q26.12, 11q13.4, and 14q23-24) are not associated with known tumor suppressors. These sites need validation and further study.
Frequency map. We derived a map of CNA frequency (Fig.  5) in GBM with an average resolution of f1.4 Mb. The map suggests that several mechanisms of genomic instability operate in GBM. These include whole chromosome gain and loss (e.g., chromosomes 7, 10, and 13) and smaller regions of loss and gain (e.g., loss on chromosome 3, gain on 12q). Other studies have suggested that several mechanisms target whole chromosome or parts of chromosomes in tumors. (58, 59) . Our data suggest that certain portions of chromosomes are gained (e.g., 7p11-2 EGFR and 7q35-6) or lost (e.g., regions on 10p, 10q, and Xp) at substantially different frequencies than neighboring regions. This suggests that local genetic instability plays an important role in genetic selection of these tumors. This view is supported by the variability we observe in relationships of clones on chromosome 7 and 10 to genetic subgroups.
Technical issues and data interpretation. 5 . Some BAC clones may be mapped inaccurately or hybridize poorly. A priori identification of such clones is not easy, so validation of these findings by other methods is important. We avoided including data from BAC clones with suspicious behavior and questionable mapping information. As a whole, we expect our frequency map to be f90% accurate because 90% of the BAC clones used were FISH-mapped. Our validation studies with FISH, quantitative PCR, and chromosome CGH all suggested excellent agreement. One issue for our frequency map is the reliability of CNAs limited to isolated single BAC clones. To address this issue, we selected nine such BAC clones and validated them by FISH (Table 3) . We found that aCGH provides generally reliable estimates of relative DNA copy number, although it tends to underestimate higher copy number. We did find that FISH copy number for BACs RP11-96L18, RO11-123E05, and RP11-95N10 were aberrant. Based on these observations, we believe that isolated single aberrant BAC clones indicate a real loss or gain in >50% of cases.
More than 90% of chromosome CGH scores agreed with aCGH results (Table 2) . Disagreements were infrequent and were matters of degree. Obvious differences between chromosome CGH and aCGH that could produce such disagreements include (a) hybridization dynamics-chromosome CGH displays CNAs on single metaphase chromosomes and aCGH displays them on 100-to 200-kb segments of the human genome cloned into BACs and (b) cutoffs-aCGH cutoffs were calculated from objective criteria, whereas analysis of chromosome CGH depended on more subjective observations.
Conclusion
These experiments detail genetic CNAs detected in a series of GBM. The CNAs support previous work that describes oncogenes and tumor suppressors associated with this tumor, and suggest several candidate loci that need to be validated and further investigated. Our data also suggest that there are genetic subgroups within GBM. This raises the possibility that each subgroup may need different therapies for optimal treatment.
